Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01613
|
|||||
| Drug Name |
MG-132
|
|||||
| Synonyms |
MG-132; Z-Leu-leu-leu-al; MG132; Zlllal; MG 132; Z-LLL-CHO; Zlll-cho; Z-Leu-leu-leucinal; Z-Leu-Leu-Leu-H; Z-Leu-Leu-Leu-CHO; Carbobenzoxy-leucyl-leucyl-leucinal; UNII-RF1P63GW3K; Benzyloxycarbonyl-leu-leu-leu-aldehyde; Benzyloxycarbonyl-leucyl-leucyl-leucinal; Lll cpd; Carbobenzoxyl-leucinyl-leucinyl-leucinal-H; Cbz-Leu-Leu-Leu-H; Benzyloxycarbonylleucyl-leucyl-leucine aldehyde; benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; RF1P63GW3K
|
|||||
| Indication | Cancer [ICD11: 2A00-2F9Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H41N3O5
|
|||||
| Canonical SMILES |
CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1
|
|||||
| InChI |
InChI=1S/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)/t21-,22-,23-/m0/s1
|
|||||
| InChIKey |
TZYWCYJVHRLUCT-VABKMULXSA-N
|
|||||
| CAS Number |
CAS 133407-82-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 475.6 | Topological Polar Surface Area | 114 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 15 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
4.8
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:75142
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Merck Sharp & Dohme: MG-132 | |||||
| 2 | Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem. 2010;74(9):1913-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.